Press
News you can check against the source
Naprod's press page publishes only stories that can be independently verified: a regulator's own register, a named trade publication, or a dated company announcement. Nothing here is a press release dressed up as news.
4 stories on record since January 2026, including one third-party-verified regulatory milestone: ANVISA's January 2026 GMP renewal, reported by Pharma India Magazine.
Featured
ANVISA Renews GMP Certification for Naprod's Tarapur Sterile-Oncology Facility
Brazil's national health regulatory authority renewed Good Manufacturing Practice certification for Naprod's Tarapur plant in January 2026, keeping the sterile oncology injectables facility qualified to supply the Brazilian and wider Mercosur market.
Source: Pharma India Magazine and Medical Dialogues
Read the full story →Dated trail
Every other entry, dated and sourced
Company announcements are labeled as such and are not presented as independently verified unless they carry a named third-party source.
-
Naprod's Tarapur Register: 15 Manufacturing Accreditations Now Confirmed From Certificates on File
Following the January 2026 ANVISA renewal, Naprod's accreditation register now shows 15 of its 21 international certifications confirmed from the issued certificate held on file, with 6 more being digitized for publication.
Naprod Life Sciences (company announcement) -
Naprod to Showcase Oncology and Lyophilized Injectables at CPHI South East Asia 2026
Naprod Life Sciences will exhibit its oncology, injectable, and lyophilized formulation capabilities at CPHI South East Asia 2026 in Bangkok (Booth B31, 8–10 July 2026), inviting distributors and partners to discuss supply and partnership opportunities.
Naprod Life Sciences (LinkedIn) -
Naprod Appoints Smita Kadam as DGM, International Business
Naprod Life Sciences announced the appointment of Smita Kadam as Deputy General Manager, International Business, bringing 15 years of international business-development experience to strengthen the company's expansion across Latin America.
Naprod Life Sciences (LinkedIn) -
Naprod Reaffirms Oncology Supply Continuity Amid Platinum Raw-Material Constraints
Naprod Life Sciences stated its commitment to uninterrupted supply of platinum-based oncology injectables, including Cisplatin and Carboplatin, as industry-wide raw-material constraints affect availability, focusing on supply continuity for healthcare institutions.
Naprod Life Sciences (LinkedIn) -
Naprod Joins Pharma Eurasia 2026 in Tashkent to Expand Across CIS Markets
Naprod Life Sciences exhibited at Pharma Eurasia 2026 at Tashkent Pharma Park, Uzbekistan (Stall D15, 20–22 May 2026), connecting with partners across the Eurasian pharmaceutical market.
Naprod Life Sciences (LinkedIn) -
Naprod Details Oncology Injectable Manufacturing Capacity at Tarapur
Company update outlining current lyophilized and liquid oncology injectable capacity at the Tarapur site, alongside the facility's broader dosage-form output.
Naprod Life Sciences (company announcement)
Freshness commitment
A press page that gets checked, not just posted
This news section was dormant since 2019 on the previous site. Going forward, every entry carries a publish date, a source line, and a verified flag. Third-party-reported items are marked verified only once checked against the named outlet or regulator register; company-sourced announcements are marked as such and never blended with independent coverage. No press releases, blog posts, award claims, or quality-programme names are published here unless they can be traced to a named, checkable source.
Pending approval Historical news content from before this rebuild (pre-2026) was not recoverable from available source material and is not represented here.
For press & partners
Media kit and press contact
A downloadable media kit (company backgrounder, Tarapur facility fact sheet, and approved logo assets) is in preparation. Press and regulatory-affairs inquiries can be directed to Naprod's Quality & Regulatory team; a named press contact will be published here once confirmed by the company.
Pending approval Media kit assets and a named press contact are PENDING APPROVAL; this section will link directly to the kit and list a contact once the company confirms them.